pharmaceutical investing Zealand Pharma Doses First Patient in Phase 3 Trial with Dasiglucagon for Treatment of Congenital Hyperinsulinism
pharmaceutical investing BioCryst Reports Agreement with PMDA on Phase 3 Clinical Trial and Regulatory Requirements for Marketing Authorization of BCX7353 in Japan
pharmaceutical investing Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
pharmaceutical investing Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
pharmaceutical investing Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05
pharmaceutical investing Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
Metalsource Mining Launches Major Step Out Program With 1.1 km Northern Target to Test Broader Scale of Silver Hill
Skyharbour Commences Drilling at the Getty East Uranium Joint Venture with Partner Denison Mines at the Russell Lake Project Area
